79- Regueiro M, El-Hachem S, Kip KE, Schraut W, Baidoo L, Watson A, et al. Postoperative
infliximab is not associated with an increase in adverse events in Crohn’s disease. Dig Dis Sci.
2011;56(12):3610–5. - Yamamoto T, Umegae S, Matsumoto K. Impact of infliximab therapy after early endoscopic
recurrence following ileocolonic resection of Crohn’s disease: a prospective pilot study.
Inflamm Bowel Dis. 2009;15(10):1460–6. - De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, et al. Crohn’s
disease management after intestinal resection: a randomised trial. Lancet (London, England).
2015;385(9976):1406–17. - Ferrante M, Papamichael K, Duricova D, D’Haens G, Vermeire S, Archavlis E, et al. Systematic
versus endoscopy-driven treatment with azathioprine to prevent postoperative ileal Crohn’s
disease recurrence. J Crohns Colitis. 2015;9(8):617–24. - Connelly TM, Messaris E. Predictors of recurrence of Crohn’s disease after ileocolectomy: a
review. World J Gastroenterol. 2014;20(39):14393–406. - Regueiro M. Management and prevention of postoperative Crohn’s disease. Inflamm Bowel
Dis. 2009;15(10):1583–90. - Regueiro M, Velayos F, Greer JB, Bougatsos C, Chou R, Sultan S, Singh S. American
gastroenterological association technical review in the management of crohn’s disease after
surgical resection. Gastroenterology. 2017;152(1):277–95
5 Use of Biologics in the Postoperative Management of Crohn’s Disease